WilmerHale Advises Infinity Pharmaceuticals in Definitive Merger Agreement with MEI Pharma

WilmerHale Advises Infinity Pharmaceuticals in Definitive Merger Agreement with MEI Pharma

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Critical industry insight and formidable strength across key practices.

On February 23, 2023, Infinity Pharmaceuticals and MEI Pharma announced that the companies have entered into a definitive merger agreement for an all-stock transaction forming a company combining the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates. Headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals is a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate. MEI Pharma is a clinical-stage pharmaceutical company focused on advancing new therapies for cancer. 

The WilmerHale team advising Infinity Pharmaceuticals included Hal Leibowitz, Michael Gilligan, Cynthia Mazareas and Judd Abramson. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel